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S U M M A R Y
Objectives: Non-structural protein 1 (NS1)-based tests may offer a larger window of opportunity for
dengue diagnosis and could constitute a very useful diagnostic tool. The aim of this study was to
establish the overall accuracy of NS1-based tests for diagnosing dengue infection.
Methods: A meta-analysis was conducted including 18 studies published up to October 1, 2012
identiﬁed using PubMed, ISI Web of Science, Google Scholar, and the Chinese National Knowledge
Infrastructure (CNKI) database.
Results: For the single NS1-based tests – ELISA (Panbio Dengue Early ELISA Kit, Dengue NS1 Ag ELISA Kit,
and Platelia Dengue NS1 Ag-ELISA Kit) and immunochromatography (Dengue NS1 Ag STRIP Kit and SD
BIOLINE Dengue Duo Strip Kit) – the summarized sensitivities and speciﬁcities were 67% (95% conﬁdence
interval (CI) 59–74%) and 99% (95% CI 97–99%), and 71% (95% CI 61–79%) and 99% (95% CI 98–100%),
respectively. The hierarchical summary receiver operating characteristics (HSROCs) were 0.92 and 0.96,
respectively. For NS1 combined with an anti-dengue-speciﬁc IgM test, the summarized sensitivity,
speciﬁcity, and HSROC were 83% (95% CI 68–92%), 86% (95% CI 79–91%), and 0.91 (95% CI 0.89-0.93),
respectively. The accuracy for serotypes was 50.0–90.9% for DENV-1, 38.5–85.7% for DENV-2, 46.7–91.3%
for DENV-3, and 21.7–87.0% for DENV-4.
Conclusions: These results support the use of single NS1-based tests; they have good diagnostic utility
for conﬁrming dengue and for distinguishing serotypes DENV-1 and 3 from DENV-2 and 4, while they
can be used as a screening tool when combined with an IgM test. Moreover, the Dengue NS1 Ag STRIP Kit
appears to be the best for conﬁrming and serotyping dengue infection.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Dengue is a vector-borne disease caused by dengue virus
(DENV), occurring throughout tropical and subtropical areas. It has
become one of the most serious public health problems due to the
increasing morbidity.1 The World Health Organization (WHO)
2009 guidelines identify three diagnostic tests as gold standardsE-mail address: xgchen2001@hotmail.com.
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(Y. Zhou).
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1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).for dengue diagnosis: viral isolation and identiﬁcation, nucleotide
detection, and serological tests for IgM or IgG seroconversion.2
However, these have limitations, such as requests for acute
infection (0–5 days post-onset) samples, the time required for viral
isolation and identiﬁcation (more than 1 week), the possibility of
false-positive or false-negative ﬁnal results, and the need for
further serum samples to conﬁrm serological tests.3
An affordable, time-saving, and convenient diagnostic test for
conﬁrming dengue infection is thus urgently needed. It was
recently reported that serum or plasma DENV non-structural
protein 1 (NS1) can be detected in the peripheral blood from 9 to 18
days after illness onset.4–7 Thus, the detection of NS1 may offer a
larger window of opportunity for dengue diagnosis. NS1-captureciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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The two main methods for detecting dengue virus infection are
currently ELISA (Panbio Dengue Early ELISA Kit, Dengue NS1 Ag
ELISA Kit, and Platelia Dengue NS1 Ag-ELISA Kit) and immuno-
chromatography (Dengue NS1 Ag STRIP Kit and SD BIOLINE
Dengue Duo Strip Kit). Many of these have shown results
comparable to those of the gold standard detection methods
(antibody detection, nucleotide detection, or viral identiﬁcation).
We conducted a meta-analysis to comprehensively assess the
performance of NS1-based detection in the evaluation of dengue.
Through this analysis, we provide evidence of the adequate
sensitivities and speciﬁcities of NS1-based tests for the diagnosis of
dengue in a large population.
2. Materials and methods
2.1. Data sources and searches
A search was performed to identify published articles reporting
studies of dengue diagnosis methods, including virus isolation and
identiﬁcation, RNA detection, serological tests for IgM or IgG
seroconversion, and the NS1-based capture method. NCBI PubMed,
ISI Web of Science, Google Scholar, and the Chinese National
Knowledge Infrastructure (CNKI) databases were searched for
studies published prior to October 1, 2012, using the following
search terms: dengue, NS1 or non-structure 1, diagnosis. No
language limitation was applied.
2.2. Selection criteria
For inclusion, studies had to meet the following criteria: (1)
patients or samples with dengue infection conﬁrmed by one of the
three standard methods (viral isolation and identiﬁcation, RNA
detection, or serological tests for IgM and/or IgG seroconversion);
(2) patients or samples also investigated by NS1-based capture
method combined or not with an IgM test; (3) report of the data
necessary to calculate the true positive, false positive, true
negative, and false negative diagnostic results of NS1 for dengue
diagnosis; (4) the inclusion of at least 50 samples from participants
and a control group respectively, for good reliability; (5) a Quality
Assessment for Diagnostic Accuracy Studies (QUADAS)8 score of
<6. Studies with an overlapping patient sample were excluded;
only the study with the larger number of patients was included.
In order to evaluate the accuracy of serotyping of dengue, the
studies that reported dengue serotyping were also retrieved. These
studies had to meet the following criteria: (1) the inclusion of
information on the serotyping of dengue by NS1-based captured
test, and also accompanied by an RT-PCR test; (2) no fewer than
100 participants.
2.3. Study selection and data extraction
The eligible studies were assessed independently by two of the
authors and were veriﬁed reciprocally, with disagreements
resolved in consultation with a third investigator. The data were
extracted independently by two investigators. For each study, the
following information was abstracted: author, study publication
year, country, study design, study population, number of patients
or samples, the standard methods used, and the NS1-based capture
method used. True positive, false positive, true negative, and false
negative results were extracted, allowing the calculation of
sensitivity, speciﬁcity, positive predictive value (PPV), and nega-
tive predictive value (NPV) for each reported test threshold. For the
accuracy of serotyping analysis, the percentage, author, publica-
tion year, and total number of participants were extracted.2.4. Quality assessment
The quality of the studies included in the meta-analysis was
assessed using the QUADAS questionnaire. The QUADAS tool has
11 items that assess study design-related issues and the validity
of the results of the study. Each item may be scored ‘yes’ if
reported (1 point), ‘no’ if not reported, or ‘unclear’ if there is no
adequate information in the article to make an accurate
judgment (0 points). If the QUADAS score was <6 points, the
study was classiﬁed as low methodological quality and was
excluded.
2.5. Data synthesis and statistical analysis
The summarized sensitivity, speciﬁcity, and diagnostic odds
ratio (OR) with corresponding 95% conﬁdence interval (CI) were
used to examine the accuracy of NS1 tests for dengue. The
diagnostic OR represents how much larger the odds of dengue
infection is for those with positive test results than the odds of
dengue infection for those with negative test results. The
diagnostic OR is calculated as follows: diagnostic OR = positive
likelihood ratio/negative likelihood ratio. A hierarchical summa-
rized receiver operating characteristic (HSROC) curve9 was also
plotted to graphically present the results. The heterogeneity
among studies was evaluated by computing Higgins’ I2 and Q tests
using the generic inverse variance method of meta-analysis of
diagnostic OR. An I2 value of >50% or a p-value of <0.05 was
considered substantial heterogeneity. If heterogeneity existed
between primary studies, the random effect method was used for
pooled analyses.
In addition, a meta-regression technique was used according to
the following pre-deﬁned characteristics, to explore source of
heterogeneity in the studies: different kits, study design, publica-
tion year, sample size, and QUADAS score. A p-value of <0.05 was
considered to be representative of statistical signiﬁcance. The
Deeks funnel plot asymmetry test was used to investigate
publication bias.10
Pre-test probabilities of 25%, 50%, and 75% vs. corresponding
post-test probabilities were evaluated. This was followed by a
‘positive’ or ‘negative’ NS1 result based on the summarized
sensitivity and speciﬁcity using Fagan plot analysis, which showed
the relationship between the prior probability speciﬁed, the
likelihood ratio, and the posterior test probability (a ruler for
interpreting diagnostic test results). Analyses were performed
using STATA version 11.0 (Stata Corp., College Station, TX, USA) and
the orders of Metandi11 and Midas.12
The percentage of correct serotype identiﬁcation using NS1-
based capture methods was calculated. The accuracy for each
serotype was also calculated. The graphs were drawn using
GraphPad Prism 5 and Photoshop software.
3. Results
3.1. Search results
On the basis of the described search strategies, a total of 268
articles were retrieved. After eliminating the duplicates (n = 11)
and the studies not related to the topic (n = 213), 44 potentially
relevant studies were identiﬁed for further evaluation. A further 14
studies were excluded as it was not possible to extract the
statistics, 10 were excluded for small sample sizes, and two were
excluded for low quality. Thus, 18 studies in total met the inclusion
criteria. A ﬂow chart of the study selection process is shown in
Figure 1. For the evaluation of accuracy of serotyping, another two
studies were included.13,14
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A total of 12 313 patients and samples were included. Six
commercially available NS1-based capture tests were used: seven
studies referred to the use of Panbio Dengue Early ELISA (Inverness,
Brisbane, Australia),15–21 three to the Dengue NS1 Ag ELISA Kit
(Standard Diagnostic Inc., Kyonggi-do, South Korea),15,19,22 11 to
Platelia Dengue NS1 Ag-ELISA (Bio-Rad Laboratories -Marnes La
Coquette, Franc),15–19,23–28 nine to Dengue NS1 Ag STRIP Kit (Bio-
Rad),15–18,27,29–32 two to SD BIOLINE Dengue Duo Strip Kit
(Standard diagnostic Inc.),15,32 and three to NS1-based capture
combined with IgM test15,20,32 for dengue. According to the
QUADAS scale, the studies included were of very good methodo-
logical quality. The main characteristics of the studies included in
this meta-analysis are summarized in Tables 1–3.
3.3. Diagnostic accuracy of the ELISA method, including Panbio
Dengue Early ELISA Kit, Dengue NS1 Ag ELISA Kit, and Platelia Dengue
NS1 Ag-ELISA Kit
Fourteen studies evaluated the diagnostic accuracy of the
commercial kits Panbio Dengue Early ELISA, Dengue NS1 Ag ELISA
Kit, and Platelia Dengue NS1 Ag-ELISA Kit for dengue (Table 1). The
sensitivity and speciﬁcity of diagnosis for dengue ranged from 37%
(95% CI 24–52%) to 96% (95% CI 95–99%) and 89% (95% CI 81–95%)
to 100% (95% CI 95–100%), respectively. The summarized
sensitivity and speciﬁcity were 67% (95% CI 59–74%) and 99%
(98% CI 97–99%), respectively. The summarized diagnostic OR was
148 (95% CI 51–492) and HSROC was 0.92 (95% CI 0.89–0.94)
(Figure 2A). On the basis of these values, PPV and NPV were 0.98
(95% CI 0.96–0.99) and 0.73 (95% CI 0.72–0.74), respectively. ThereFigure 1. Flow diagram of selectiowas statistically signiﬁcant heterogeneity in diagnostic OR
(Q = 55.47, p < 0.001, I2 = 96%). According to the meta-regression
analysis, the accuracy of these three kits for detecting dengue was
affected by study design, while the result was not changed (data
not shown). Publication bias did not exist among these studies
(p = 0.06).
Fagan plot analysis demonstrated that the ELISA method was
very informative, with 94% probability of correctly detecting
dengue following a ‘positive’ measurement when the pre-test
probability was 25% and lowering the probability of disease to as
low as 10% with a ‘negative’ measurement. This diagnosis would be
wrong in 25% and 50% of patients with a ‘negative’ measurement
when the pre-test probability was 50% and 75%, respectively,
although the probability of a correct diagnosis following a ‘positive’
measurement equaled 98% and 99% for dengue, respectively
(Table 4, Figure 3).
Seven studies evaluated the diagnostic accuracy of the
commercial kit Panbio Dengue Early ELISA (Table 1 and Table 4)
for dengue. The summarized sensitivity and speciﬁcity were 67%
(95% CI 59–74%) and 99% (95% CI 97–99%), respectively. The
summarized diagnostic OR was 127 (95% CI 20–804) and HSROC
was 0.80 (95% CI 0.76–0.83). On the basis of these values, PPV and
NPV were 0.98 (95% CI 0.98–1.00) and 0.71 (95% CI 0.76–0.83),
respectively. Fagan plot analysis demonstrated that this method
was very informative, with 94% probability of correctly detecting
dengue following a ‘positive’ measurement when the pre-test
probability was 25% and lowering the probability of disease to as
low as 11% with a ‘negative’ measurement. This diagnosis would be
wrong in 27% and 53% of patients with a ‘negative’ measurement
when the pre-test probability was 50% and 75%, respectively,
although the probability of a correct diagnosis following a ‘positive’n and disposition of studies.
Table 1
Diagnostic accuracy results of individual studies using the ELISA method, including the commercial kits Panbio Dengue Early ELISA, Dengue NS1 Ag ELISA, and Platelia Dengue
NS1 Ag-ELISA
Author (year) Geography Design Size Conﬁrmed
testsa
TP FP FN TN Sensitivity
% (95% CI)
Speciﬁcity
% (95% CI)
PPV % NPV % QUADAS
Ramirez et al. (2009)b South America (Venezuela) Retrospective 147 1 53 2 34 58 61 (50–71) 97 (98–100) 96 63 8
Watthanaworawit
et al. (2010)b
Southeast Asia
(Thailand/Myanmar)
Prospective 152 3 39 0 33 90 54 (42–66) 100 (96–100) 100 73 10
Osorio et al. (2010)b South America (Colombia) Retrospective 400 1 155 10 63 82 71 (65–77) 89 (81–95) 94 57 11
Lima et al. (2010)b South America (Brazil) Prospective 550 1 159 0 61 230 72 (66–78) 100 (88–100) 100 79 9
Pok et al. (2010)b Southeast Asia (Singapore) Prospective 209 2 73 0 36 100 67 (57–76) 100 (96–100) 100 74 8
Fry et al. (2011)b Southeast Asia (Vietnam) Prospective 298 4 137 4 61 96 69 (62–76) 96 (90–99) 97 61 9
Blacksell et al. (2012)b Southeast Asia (Thailand),
Asia (Sri Lanka)
Retrospective 387 2 107 12 132 136 45 (38–51) 92 (86–96) 90 51 10
Osorio et al. (2010)c South America (Colombia) Retrospective 400 1 150 5 68 87 69 (62–75) 95 (88–96) 97 56 11
Wang et al. (2010)c Southeast Asia (Malaya) Prospective 244 1 142 1 43 58 77 (70–83) 98 (91–100) 99 57 9
Blacksell et al. (2012)c Southeast Asia(Thailand),
Asia (Sri Lanka)
Retrospective 387 2 132 2 107 146 55 (49–62) 99 (95–100) 99 58 10
Kumarasamy
et al. (2007)d
Southeast Asia (Malaysia) Retrospective 567 2 199 0 4 354 96 (95–99) 100 (96–100) 100 99 8
Lapphra et al. (2008)d Southeast Asia (Thailand) Prospective 235 1 108 1 63 63 63 (55–70) 96 (92–100) 99 50 11
Ramirez et al. (2009)d South America (Venezuela) Retrospective 143 1 62 5 25 55 71 (61–80) 92 (82–97) 93 69 8
Phuong et al. (2009)d Southeast Asia (Vietnam) Prospective 459 2 20 2 34 403 37 (24–52) 100 (96–100) 91 92 8
Osorio et al. (2010)d South America (Colombia) Retrospective 400 1 150 7 62 84 71 (64–77) 92 (85–97) 96 56 11
Lima et al. (2010)d South America (Brazil) Prospective 550 1 184 3 36 227 84 (78–88) 99 (85–97) 98 86 10
Pok et al. (2010)d Southeast Asia (Singapore) Prospective 209 2 89 0 20 100 82 (73–88) 100 (96–100) 100 45 8
Duong et al. (2011)d Southeast Asia (Cambodia) Prospective 359 5 150 0 110 79 58 (51–64) 100 (95–100) 100 42 8
Najioullah et al. (2011)d North America (Martinique) Prospective 537 3 156 0 99 271 61 (55–67) 100 (96–100) 100 73 10
Kassim et al. (2011)d Southeast Asia (Malaysia) Retrospective 208 3 60 7 77 64 44 (35–53) 90 (81–96) 90 45 7
Blacksell et al. (2012)d Southeast Asia(Thailand),
Asia (Sri Lanka)
Retrospective 387 2 107 12 132 136 45 (38–51) 92 (86–96) 90 51 9
TP, true positive; FP, false positive; FN, false negative; TN, true negative; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value; QUADAS,
Quality Assessment for Diagnostic Accuracy Studies.
a Conﬁrmed tests: (1) serological, nucleotide, or viral culture test; (2) serological or nucleotide test; (3) serological test; (4) nucleotide test; (5) serological, NS1 detection,
nucleotide, or viral culture test.
b Statistics retrieved from studies using the Panbio Dengue Early ELISA Kit.
c Statistics retrieved from studies using the Dengue NS1 Ag ELISA Kit.
d Statistics retrieved from studies using the Platelia Dengue NS1 Ag-ELISA.
Table 2
Diagnostic accuracy results of individual studies using the immunochromatography method, including the commercial kit Dengue NS1 Ag STRIP Kit and SD BIOLINE Dengue
Duo Strip Kit
Author (year) Geography Design Size (time) Conﬁrmed
testsa
TP FP FN TN Sensitivity
% (95% CI)
Speciﬁcity
% (95% CI)
PPV % NPV % QUADAS
Shu et al. (2009)b Asia Retrospective 162 (15/30 min) 4 82 0 40 50 67 (58–75) 100 (93–100) 100 56 7
Ramirez et al. (2009)b South America
(Venezuela)
Retrospective 147 (30 min) 1 59 2 28 58 68 (57–77) 97 (88–100) 97 67 8
Zainah et al. (2009)b Southeast Asia
(Malaya)
Retrospective 533 (15/30 min) 1 284 1 30 218 49 (43–56) 100 (97–100) 100 88 9
Osorio et al. (2010)c South America
(Colombia)
Retrospective 400 (NR) 1 111 3 107 89 51 (44–58) 97 (91–99) 97 45 11
Lima et al. (2010)b South America
(Brazil)
Prospective 550 (15/30 min) 1 197 2 23 228 90 (85–93) 99 (97–100) 99 91 10
Pok et al. (2010)b Southeast Asia (Singapore) Prospective 209 (NR) 2 86 1 23 99 79 (70–86) 99 (95–100) 99 81 8
Chaterji et al. (2011)b Southeast Asia (Singapore) Prospective 354 (15 min) 3 119 0 35 200 77 (70–86) 100 (98–100) 100 85 10
Chaterji et al. (2011)b Europe (Singapore) Prospective 354 (30 min) 3 124 0 30 200 77 (70–84) 100 (98–100 100 87 10
Najioullah et al. (2011)b Southeast Asia
(Martinique)
Prospective 537 (30 min) 4 125 0 128 272 81 (73–86) 100 (99–100) 100 68 10
Blacksell et al. (2011)b Asia (Sri Lanka) Prospective 259 (NR) 2 58 2 41 158 90 (87–93) 99 (96–100) 97 79 10
Blacksell et al. (2011)b Asia (Sri Lanka) Prospective 259 (NR) 2 58 12 41 148 59 (48–68) 93 (87–96) 83 78 10
Blacksell et al. (2011)c Asia (Sri Lanka) Prospective 259 (NR) 2 48 1 51 159 48 (38–59) 99 (97–100) 98 76 10
TP, true positive; FP, false positive; FN, false negative; TN, true negative; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value; QUADAS,
Quality Assessment for Diagnostic Accuracy Studies; NR, not reported.
a Conﬁrmed tests: (1) serological, nucleotide, or viral culture test; (2) serological or nucleotide test; (3) viral culture or nucleotide test; (4) nucleotide test.
b Statistics retrieved from studies using the Dengue NS1 Ag STRIP Kit.
c Statistics retrieved from studies using the SD BIOLINE Dengue Duo Strip Kit.
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(Table 4).
Eleven studies evaluated the diagnostic accuracy of the
commercial kit Platelia Dengue NS1 Ag-ELISA (Table 1 and
Table 4) for dengue. The summarized sensitivity and speciﬁcity
were 66% (95% CI 54–81%) and 99% (95% CI 96–100%), respectively.The summarized diagnostic OR was 228 (95% CI 36–1456) and
HSROC was 0.95 (95% CI 0.92–0.96). On the basis of these values,
PPV and NPV were 0.98 (95% CI 0.97–1.00) and 0.75 (95% CI 0.74–
0.76), respectively. Fagan plot analysis demonstrated that this
method was very informative, with 94% probability of correctly
detecting dengue following a ‘positive’ measurement when the
Table 3
Diagnostic accuracy results of individual studies using NS1-based capture combined with IgM test (dengue if one of NS1 or IgM was positive and non-dengue if both were
negative)
Author (year) Geography Design Size Conﬁrmed
testsa
TP FP FN TN Sensitivity
% (95% CI)
Speciﬁcity
% (95% CI)
PPV % NPV % QUADAS
Watthanaworawit
et al. (2010)
Southeast Asia
(Thailand/Myanmar)
Prospective 162 3 43 11 29 79 60 (47–71) 88 (79–94) 80 73 10
Osorio et al. (2010) South America
(Colombia)
Retrospective 400 1 171 8 47 84 78 (72–84) 91 (84–96) 96 64 11
Blacksell et al. (2011) Southeast Asia
(Thailand), Asia
(Sri Lanka)
Retrospective 250 2 92 18 7 142 93 (86–97) 89 (83–93) 84 95 10
Blacksell et al. (2011) Southeast
Asia (Thailand),
Asia (Sri Lanka)
Retrospective 250 2 89 40 10 120 90 (82–95) 75 (68–81) 70 92 10
TP, true positive; FP, false positive; FN, false negative; TN, true negative; CI, conﬁdence interval; PPV, positive predictive value; NPV, negative predictive value; QUADAS,
Quality Assessment for Diagnostic Accuracy Studies.
a Conﬁrmed tests: (1) serological, nucleotide, or viral culture test; (2) serological or nucleotide test; (3) serological test.
Figure 2. Hierarchical summarized receiver operating characteristic (HSROC) curves of NS1-based capture tests for dengue using: (A) the method of ELISA for dengue; (B) the
method of immunochromatography for dengue; (C) NS1-based capture combined with IgM test for dengue. HSROCs for dengue were 0.92, 0.96, and 0.91, respectively.
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disease to as low as 9% with a ‘negative’ measurement. This
diagnosis would be wrong in 24% and 48% of patients with a
‘negative’ measurement when the pre-test probability was 50%
and 75%, respectively, although the probability of a correct
diagnosis following a ‘positive’ measurement equaled 98% and
99% for dengue, respectively (Table 4).
3.4. Diagnostic accuracy of the immunochromatography method,
including Dengue NS1 Ag STRIP Kit and SD BIOLINE Dengue Duo Strip
Kit for dengue
Nine studies evaluated the diagnostic accuracy of the commer-
cial kits Dengue NS1 Ag STRIP Kit and SD BIOLINE Dengue Duo Strip
Kit for dengue (Table 2). The sensitivity and speciﬁcity of diagnosis
for dengue ranged from 48% (95% CI 38–59%) to 90% (95% CI 87–
93%) and 93% (95% CI 87–96%) to 100% (95% CI 93–100%),
respectively. The summarized sensitivity and speciﬁcity were 71%
(95% CI 61–79%) and 99% (95% CI 98–100%), respectively. The
summarized diagnostic OR was 328 (95% CI 103–1046) and HSROC
was 0.96 (95% CI 0.95–0.98) (Figure 2B). On the basis of these
values, PPV and NPV were 0.99 (95% CI 0.98–1.00) and 0.75 (95% CI
0.75–0.76), respectively. There was statistically signiﬁcant het-
erogeneity in diagnostic OR (Q = 17.05, p < 0.001, I2 = 88%).
However, according to the meta-regression analysis, the accuracyof these two kits for detecting dengue was affected by study design
and publication year, while the result was not changed (data not
shown). Publication bias existed among these studies (p = 0.02).
Fagan plot analysis demonstrated that the method of immu-
nochromatography was very informative, with 97% probability of
correctly detecting dengue following a ‘positive’ measurement
when the pre-test probability was 25% and lowering the
probability of disease to as low as 9% with a ‘negative’
measurement. This diagnosis would be wrong in 23% and 52% of
patients with a ‘negative’ measurement when the pre-test
probability was 50% and 75%, respectively, although the probabili-
ty of a correct diagnosis following a ‘positive’ measurement
equaled 99% and 100% for dengue, respectively (Table 4, Figure 4).
Eight studies evaluated the diagnostic accuracy of the
commercial kit Dengue NS1 Ag STRIP Kit for dengue (Table 2
and Table 4). The summarized sensitivity and speciﬁcity were 71%
(95% CI 64–82%) and 99% (95% CI 98–100%), respectively. The
summarized diagnostic OR was 486 (95% CI 124–1902) and HSROC
was 0.96 (95% CI 0.94–0.98). On the basis of these values, PPV and
NPV were 0.99 (95% CI 0.98–1.00) and 0.78 (95% CI 0.77–0.78),
respectively. Fagan plot analysis demonstrated that this method
was very informative, with 94% probability of correctly detecting
dengue following a ‘positive’ measurement when the pre-test
probability was 25% and lowering the probability of disease to as
low as 8% with a ‘negative’ measurement. This diagnosis would be
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H. Zhang et al. / International Journal of Infectious Diseases 26 (2014) 57–6662wrong in 21% and 44% of patients with a ‘negative’ measurement
when the pre-test probability was 50% and 75%, respectively,
although the probability of a correct diagnosis following a ‘positive’
measurement equaled 98% and 99% for dengue, respectively
(Table 4).
3.5. Diagnostic accuracy of a commercial NS1-based capture kit
combined with IgM test for dengue
Three studies evaluated the diagnostic accuracy of NS1-based
capture combined with IgM test for dengue (Table 3). The
sensitivity and speciﬁcity of diagnosis for dengue ranged from
60% (95% CI 47–71%) to 93% (95% CI 86–97%) and 75% (95% CI
68–81%) to 91% (95% CI 84–96%), respectively. The summarized
sensitivity and speciﬁcity were 83% (95% CI 68–92%) and 86%
(95% CI 79–91%), respectively. The summarized diagnostic OR
was 31 (95% CI 14–70) and HSROC was 0.91 (95% CI 0.89–0.93)
(Figure 2C). On the basis of these values, PPV and NPV were 0.84
(95% CI 0.80–0.89) and 0.82 (95% CI 0.77–0.87), respectively.
There was statistically signiﬁcant heterogeneity in diagnostic OR
(Q = 23.12, p < 0.001, I2 = 91%). However, according to the meta-
regression analysis, the accuracy of this method for detecting
dengue was affected by publication year. As a result of only
three studies being included, the subgroup could not be
analyzed. No publication bias existed among these studies
(p = 0.29).
Fagan plot analysis demonstrated that this method was very
informative, with 67% probability of correctly detecting dengue
following a ‘positive’ measurement when the pre-test probability
was 25% and lowering the probability of disease to as low as 6%
with a ‘negative’ measurement. This diagnosis would be wrong in
16% and 37% of patients with a ‘negative’ measurement when the
pre-test probability was 50% and 75%, respectively, although the
probability of a correct diagnosis following a ‘positive’ measure-
ment equaled 86% and 95% for dengue, respectively (Table 4,
Figure 5).
3.6. Accuracy of serotyping for dengue by NS1-based capture tests
Six studies evaluated the accuracy of serotyping for dengue
by NS1-based capture test.13,14,19,21,22,31 The accuracy of total
serotyping for dengue ranged from 49.4% to 87.4% (Figure 5).
The highest accuracy for serotyping was found in two studies:
82.4%, and 80.5% by Dengue NS1 Ag STRIP Kit.13,31 The
percentage correct for DENV-1 was 50.0–90.9%, for DENV-2
was 38.5–85.7%, for DENV-3 was 46.7–91.3%, and for DENV-4
was 21.7–87.0% (Figure 6). The highest correct percentages for
DENV-1 (81.9% and 79.6%), DENV-2 (81.0% and 73.9%), DENV-3
(81.2%, 82.2%, and 87.0%), and DENV-4 (82.6% and 84.8%) found
in the above studies were also acquired using the Dengue NS1
Ag STRIP Kit.
4. Discussion
The dramatic increase in the global dengue burden has
promoted social interest in improving dengue diagnosis. The most
common methods for conﬁrming dengue in the laboratory are
currently serology, viral isolation, and nucleotide detection; these
tests have their own limitations. Soluble NS1 detected in the serum
or plasma of a DENV-infected patient may represent recent
infection. Although, DENV NS1 antigen capture ELISAs have been
reported to be promising tools for the diagnosis of acute dengue
infections,22,33,34 a recent study showed that NS1 tests were of low
quality for the diagnosis of dengue infection.35 Thus, in this meta-
analysis, we evaluated the performance of NS1-based captured
tests in dengue diagnosis.
Figure 3. Fagan plot analysis to evaluate the clinical utility of the ELISA method. (A) Pre-test probability = 25%; with a pre-test probability of dengue of 25%, the post-test
probabilities of dengue, given positive and negative results (post-positive and post-negative probability) were 94% and 10%, respectively. (B) Pre-test probability = 50%; with a
pre-test probability of dengue of 50%, the post-test probabilities of dengue, given positive and negative results (post-positive and post-negative probability) were 98% and
25%, respectively. (C) Pre-test probability = 75%; with a pre-test probability of dengue of 75%, the post-test probabilities of dengue, given positive and negative results (post-
positive and post-negative probability) were 99% and 50%, respectively. The Fagan plot consists of a vertical axis on the left with the pre-test probability, an axis in the middle
representing the likelihood ratio, and a vertical axis on the right representing the post-test probability (LR Negative, negative likelihood ratio; LR Positive, positive likelihood
ratio).
Figure 4. Fagan plot analysis to evaluate the clinical utility of the immunochromatography method. (A) Pre-test probability = 25%. (B) Pre-test probability = 50%. (C) Pre-test
probability = 75%.
H. Zhang et al. / International Journal of Infectious Diseases 26 (2014) 57–66 63Our results indicate that NS1-based capture tests have a high
accuracy for dengue detection. The HSROC for dengue diagnosis
using these tests ranged from 0.80 (95% CI 0.76–0.83) to 0.96 (95%
CI 0.95–0.98). The summarized speciﬁcity [from 99% (95% CI 93-
100%) to 99% (95% CI 96-100%)] and PPV [from 0.98 (95% CI 0.96-
0.99) to 0.99 (95% CI 0.98-1.00)] were extremely high (Table 4).
Fagan plot analysis showed that these could be used to diagnosedengue (when the pre-test probability is 25%), with 94%, 94%, 96%,
97%, and 98% probability of correctly diagnosing dengue following
a ‘positive’ measurement. When the pre-test probability is 50% or
75%, the post-test probability was found to remain satisfactory for
diagnosing dengue. Furthermore, a ‘negative’ measurement was
also informative, as dengue was present in only 10%, 11%, 9%, 9%,
and 8%. In this respect, the NS1-based capture method is reliable,
Figure 6. Overall accuracy of NS1-based tests for the diagnosis dengue infection.
Figure 5. Fagan plot analysis of total accuracy of typing of dengue using NS1-based captured tests. (A) Pre-test probability = 25%. (B) Pre-test probability = 50%. (C) Pre-test
probability = 75%.
H. Zhang et al. / International Journal of Infectious Diseases 26 (2014) 57–6664promising, and worth using in clinical practice to conﬁrm dengue
infection. This test could be integrated into the method for dengue
detection.
Although the summarized speciﬁcity for dengue was 99%, the
summarized sensitivity was relatively low: 67% (95% CI 59–74%),
63% (95% CI 56–70%), 69% (95% CI 54–81%), 71% (95% CI 61–79%), and71% (95% CI 64–82%). At this point, NS1-based capture tests may not
be sufﬁcient to detect dengue alone. Nevertheless, taking into
account the good performance of the NS1-based capture test, it could
be a useful tool for diagnosing and treating patients with dengue.
According to the analysis of the different kits (Panbio Dengue
Early ELISA Kit, Platelia Dengue NS1 Ag-ELISA, and Dengue NS1 Ag
H. Zhang et al. / International Journal of Infectious Diseases 26 (2014) 57–66 65STRIP Kit), it appears that the Dengue NS1 Ag STRIP Kit is the best
method for conﬁrming dengue due to its higher summarized
sensitivity, speciﬁcity, PPV, NPV, HSROC, etc. (Table 4). This is
followed by Platelia Dengue NS1 Ag-ELISA and then the Panbio
Dengue Early ELISA Kit. This might mean that the Dengue NS1 Ag
STRIP Kit is the most efﬁcient in conﬁrming dengue infections by
capturing NS1 antigen in the serum or plasma of the infected
patients. Moreover, this kit is more convenient to use as the results
can be achieved in 30 min at the most. It is also easy to perform
without the need for special laboratory equipment. Of note, these
kits gave different accuracies for conﬁrming dengue infection. This
phenomenon is caused by the samples being taken late after illness
onset, patients with secondary infections, and those with different
serotype infections, all of which will inﬂuence the accuracy of NS1-
based diagnostic tools.15,36
To improve the sensitivity of single NS1-based tests, NS1-based
capture combined with an IgM test was also evaluated. The
summarized sensitivity and NPV were actually increased to 0.83
(95% CI 0.68–0.92) and 0.82 (95% CI 0.77–0.87), much higher than
results using single NS1-based capture methods; however the
summarized speciﬁcity was decreased to 86% (95% CI 79–91%),
approximately 10% lower than that of single NS1 tests. The reason
for this decrease in speciﬁcity is that a positive IgM result in a
single sample does not conﬁrm dengue,15 which means false
positives with the IgM test. The HSROC for dengue diagnosis with
the combined detection was almost the same as with the single
NS1 detection method (0.92 and 0.96 vs. 0.91). However, the post-
test probability in the combined detection was not better than that
in the single test method according to the same pre-test
probability (data in Table 4). So, the single NS1-based captureFigure 7. Accuracy of serotymethod could be used to conﬁrm dengue infection, while the
combined test could be used in the screening of dengue infection.
The results of this meta-analysis are in accordance with those
of most of the previous studies which have shown the single
NS1-based test to be suitable for diagnosing dengue infection,
while the sensitivity is increased in combination with the IgM
test.15,17–24,28,31,32 Although the result of the combined test was
better than the single NS1-based test, the diagnosis of dengue
still needs to be improved in terms of sensitivity and other
indicators. A study has reported the use of a recombinant non-
structural protein 3 (rNS3) from all serotypes of dengue virus in
the diagnosis of dengue, and the results showed excellent
agreement with commercial kits and IgM/IgG respectively.37 So,
an NS1 antigen combined with rNS3 protein test might provide
better results in the future.
Because of the wide range of total accuracy of serotyping for
dengue, the NS1-based capture test is not a stable method for
serotyping. However, this method is suitable to distinguish the two
serotypes DENV-1 and DENV-3 from the other serotypes based on
the accuracies for DENV-1, DENV-2, DENV-3, and DENV-4. Due to
the wide range of percentages for DENV-2 and DENV-4, this
method is not applicable to distinguish these two serotypes
(DENV-2 and DENV-4) from other serotypes. Hence the total
accuracy of serotyping for dengue by this method is probably
affected by the poor accuracy with regard to DENV-2 and DENV-4.
However, for the Dengue NS1 Ag STRIP Kit, the overall accuracy for
serotyping dengue infection was approximately 80%, and this did
not vary as much as with the other kits (Figures 6 and 7). Thus, the
Dengue NS1 Ag STRIP Kit may be the better test for serotyping
dengue.ping dengue infection.
H. Zhang et al. / International Journal of Infectious Diseases 26 (2014) 57–6666As signiﬁcant heterogeneity and publication bias were present
in the analysis, caution must be taken when interpreting the
results. In addition, our study explored factors that may be the
source of heterogeneity using meta-regression analysis. Although
three speciﬁc covariates were examined, the study design and
publication year were deﬁnitely the source of heterogeneity.
However the results did not change.
Some limitations of this study should be taken into consider-
ation. First, the standard methods were serological test, viral
culture, and nucleotide detection, but not all the studies used the
same means to detect samples. Second, only four studies evaluated
the performance of NS1-based capture combined with the IgM test,
limiting the robustness of the conclusions that can be drawn. Third,
as a result of heterogeneity and publication bias, the results were
based on a random effect model so that the strength of the
evidence became weak.
In conclusion, our meta-analysis suggests that the single NS1-
based capture method could be used as a good dengue diagnosis
method with a high summarized speciﬁcity, and if combined with
an IgM test with a high sensitivity, it could be used as a screening
method. The NS1-based capture tests can be applied to distinguish
DENV-1 and DENV-3 from other serotypes. Moreover, the Dengue
NS1 Ag STRIP Kit may be the best kit for conﬁrming and serotyping
dengue infection. Large-scale, international, multicenter prospec-
tive studies are needed to further evaluate the potential role of
NS1-based capture methods in the diagnosis of dengue.
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